A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease

CONCLUSION: Our blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available.PMID:38311058 | DOI:10.4093/dmj.2023.0189

Source: Diabetes and Metabolism Journal - February 4, 2024 Category: Endocrinology Authors: Seung Joon Choi Sungjin Yoon Kyoung-Kon Kim Doojin Kim Hye Eun Lee Kwang Gi Kim Seung Kak Shin Ie Byung Park Seong Min Kim Dae Ho Lee Source Type: research